secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001396814-22-000066
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira Q3 revenue up 31% to $167.5M, GAAP net loss $0.7M; EXPAREL sales $132.6M, patent to 2041
--------------------------------------------------------------------------------

- Total revenues $167.5M (+31% YoY); EXPAREL $132.6M (+9%), ZILRETTA $26.5M.
- GAAP net loss $0.7M ($0.02 loss/share) vs prior-year net income $17.7M ($0.40).
- Non-GAAP net income $29.9M ($0.65/share); adjusted EBITDA $55.2M vs $48.1M.
- New EXPAREL composition patent (No. 11,452,691) expires Jan 2041; positive Phase 3 lower extremity nerve block results.
- CHMP positive opinion for pediatric EXPAREL use; encouraging Phase 1 data for PCRX-201 gene therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681422000066/0001396814-22-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681422000066/pcrx-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001396814-22-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer